Background: Stroke is the second most common cause of death and a major cause of disability worldwide. Risperidone is an atypical antipsychotic drug that may increase the risk of stroke. The present work examined whether risperidone enhances the vulnerability to stroke in hypertensive rats and the potential mechanisms underlying such action. Methods: Experiment 1: Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone SHRs (SHR-SPs) were treated with risperidone (0.8 and 2.4 mg/kg/d) or vehicle for 30 consecutive days. Tissue damage in response to middle cerebral artery occlusion (MCAO) was measured microscopically. The activity of superoxide dismutase, glutathione peroxidase, the levels of malondialdehyde were also determined. Experiment 2: Survival data were recorded in SHR-SPs that received daily risperidone perpetually. Experiment 3: Effect of risperidone on interleukin-6 and tumor necrosis factor-α was examined in quiescent or LPS-activated cortical microglias from WKY rats. Experiment 4: Potential damage of risperidone exposure to neurons was examined in primary neuronal culture obtained from WKY rats, SHRs, and SHR-SPs. Results: Risperidone increased infarct areas upon MCAO in SHR-SPs and SHRs, but not in WKY rats. Survival time in SHR-SPs was shortened by risperidone. Apoptosis was augmented by risperidone through enhanced Bax. Risperidone also increased endothelial injury. Conclusions: Risperidone enhances the vulnerability to stroke in hypertensive rats through increasing neuronal apoptosis and endothelial injury.
Introduction
Stroke is the second most common cause of death and a major cause of disability worldwide [1] [2] [3] [4] . According to a recent report published by the World Health Organization, about 15 million people per year fall victim to stroke, of whom 5 million die and another 5 million are left permanently disabled [5] . Many stroke survivors require lifelong assistance.
Risperidone is an atypical antipsychotic drug that alleviates both positive and negative symptoms and improves cognitive function in schizophrenic patients [6] [7] [8] . Risperidone produces a series of side effects, including extrapyramidal symptoms, hyperprolactinemia, and weight gain [9] . It could also unmask preexisting type 2 diabetes [9] . Clinical studies in the last decade indicated that risperidone may increase the risk of stroke [10] [11] [12] . Such a concern led to official warnings by the FDA [13] [14] [15] [16] and many debates [17] [18] [19] .
In the current study, we compared the effects of risperidone in normotensive Wistar-Kyoto (WKY) rats, spontaneously hypertensive rats (SHRs) and stroke-prone spontaneously hypertensive rats (SHR-SPs). Results showed that risperidone sensitized the brain to middle cerebral artery occlusion (MCAO) injury in hypertensive rats. Risperidone also shortened the survival time of SHR-SPs. Oxidative stress, inflammation, apoptosis, and endothelial injury were examined as potential contributing mechanisms.
Methods

Animals
WKY rats, SHRs, and SHR-SPs were provided by the Animal Center of the Second Military Medical University, and housed at 23-25 • C, with 12/12 h lighting schedule (8:00-20:00 light, 20:00-8:00 dark) and free access to standard food and drinking water. All animal subjects used in this experiment received humane care in compliance with institutional guidelines for health and care of experimental animals. 
Protocol
Experiment 1: Effect of Risperidone on Brain Damage upon MCAO
WKY rats, SHRs, and SHR-SPs (20-22 weeks of age) received daily risperidone (Hengyuan Co., Huzhou, China; 0.8 or 2.4 mg/kg, through food) or vehicle for 30 consecutive days (n = 10-20 per group). Risperidone was milled into rat chow to avoid stress associated with gastric gavage. Food consumption was monitored daily to ensure accurate dosing. Systolic blood pressure (SBP) was measured at the end of the dosing regimen using tail-cuff plethysmography [20] , before MCAO (methods in supplement) [21] [22] [23] . The infarct area was examined 24 h after MCAO. The activity of superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and the levels of malondialdehyde (MDA) in the mitochondrial fraction were determined (methods in supplement) [24, 25] . Cerebral ultramicroscopic structure morphology was observed using an electron microscope (methods in supplement) [26] .
Experiment 2: Effect of Risperidone on Life Span
SHR-SPs (20-22 weeks of age) received daily risperidone (0.8 or 2.4 mg/kg, through food) or vehicle for lifelong treatment (n = 15 per group). Rats were observed twice daily (at 8 AM and 6 PM).
Experiment 3: Effect of Risperidone on Inflammation in Cortical Microglias
Effects of risperidone on proinflammatory cytokines were examined in primary cultures of cortical microglias (methods in supplement) [27] from WKY rats. In brief, cultured microglia (quiescent vs. LPS activated, 1 μg/mL) were exposed to risperidone (0.3, 1, 3, 30 μM) or vehicle (0.4% DMSO) for 1 h. Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) was examined with ELISA kits (Shanghai Transhold Tech. Dev. Co. Ltd, Shanghai, China) [28] .
Experiment 4: Effects of Risperidone on Cell Viability and Apoptosis of Neurons
Primary neuronal culture was established from fetal WKY rats, SHRs, and SHR-SPs (methods in supplement) [29] . Cultured neurons were treated with risperidone (30, 60, 90 μM) or vehicle for 1 h before oxygen-glucose deprivation (OGD) or exposure to hydrogen peroxide (H 2 O 2 ; 100 μM; methods in supplement) [30] . The cell viability was examined by MTT assay (methods in supplement) [31] . Apoptosis was examined by flow cytometry (methods in supplement) [32] and TUNEL (methods in supplement) [33] . Expression of Bax, Bcl-2, and caspase-8 was examined by Western blot (methods in supplement) [34] . 
Statistical Analysis
Investigators were blind to the procedures during blood pressure recording, weighing and morphological examination. Data are expressed as mean ± SD, and were analyzed with ANOVA, followed by Dunnett t-test for post hoc comparison. Kaplan-Meier analysis was used to estimate survival probabilities. Log-Rank testing was used to evaluate equality of survival curves. P< 0.05 was considered statistically significant.
Results
Risperidone dose dependently increased the infarct area induced by MCAO in SHR-SPs (from 14.8% ± 1.5% in control rats to 19.3 ± 2.7% and 21.3 ± 1.9% in rats receiving 0.8 and 2.4 mg/kg/d risperidone, respectively; P = 0.0263 and P = 0.0001, respectively; Figure 1A ). Similar findings were observed in SHRs but not in WKY rats ( Figure 1A ). Risperidone did not influence the body weight and SBP in any rat strain ( Figure S1A ). Activity of SOD, GSH-Px, and the level of MDA in ischemic brain tissue were not affected ( Figure S2 ).
Lifelong treatment of risperidone decreased the life span of SHRSPs at a dose of 2.4 mg/kg/d (318 ± 53 days vs. 362 ± 53 days in the control rats; P = 0.0472, log-rank test), but not at a lower dose of 0.8 mg/kg/d (379 ± 58 days vs. 362 ± 53 days in the control rats; P = 0.3368, log-rank test; Figure 1B) . In nearly all subjects, death was caused by stroke as verified by symptoms and/or postmortem morphology observation.
Risperidone did not affect the expression of IL-6 and TNF-α in quiescent or LPS-induced microglias of WKY rats ( Figure S2 ).
Risperidone dose dependently increased the number of apoptic cells induced by OGD or H 2 O 2 exposure and attenuated the cell viability in cultured neurons obtained from SHRs and SHR-SPs (more significantly in latter), but not in neurons obtained from WKY rats (flow cytometry, Figure 2A ; MTT, Figure 2B ; TUNEL, Figure 3 ). Risperidone did not affect cell viability ( Figure S3A ) and apoptosis ( Figure S3B ) in cultured cells not exposed to OGD or H 2 O 2 .
MCAO resulted in mitochondrial swelling in neurons, microglia, and capillary endothelial damage ( Figure 4A ). Risperidone increased capillary endothelial vacuoles and edema around the capillaries, aggravated the mitochondrial swelling, ridge loss and membrane rupture, chromatin aggregation, and lysosomes formation. Such actions were more significant in SHR-SPs than in WKY rats.
Risperidone increased the expression of Bax dose dependently (from 1.0 ± 0.15 in control group to 1.79 ± 0.21, 2.30 ± 0.30, and 2.89 ± 0.35 in groups receiving 30, 60, and 90 μM risperidone, respectively; P = 0.0395, P = 0.0063, and P = 0.0012, respectively; Figure 5A ). The expression of Bcl-2 and caspase-8 was not affected (Figures 5B and C) .
Discussion
The main findings of the present work may be summarized as: (1) SHRs, but not in WKY rats; (2) risperidone shortens the life span of SHR-SPs; (3) risperidone aggravates neuron apoptosis in SHR-SPs and SHRs, but not in WKY rats. The risk of stroke associated with risperidone remains controversial up to date [17, [35] [36] [37] [38] . In SHR-SPs, a widely used stroke model, risperidone increased the infarct area after MCAO, aggravated the damage to cerebral ultramicroscopic structure, and shortened the life span. Similar results were found in SHRs, but not in normotensive WKY rats. These findings were if clinical relevance: risperidone should be avoided in hypertensive patients.
Hypertension is a modifiable factor for stroke [3] . Risperidone is not powerful enough to induce stroke independently, but may aggravate the effects of hypertension on the development of stroke.
Results from the current study clearly indicated that risperidone could aggravate cerebral capillary damage. Risperidone did not influence the expression of proinflammatory cytokines, IL-6 and TNF-α and the oxidative stress index, SOD, MDA, GSH-Px.
Risperidone significantly promoted neuronal apoptosis in primary culture obtained from SHRs and SHR-SPs but not normotensive WKY rats. There are two major pathways for apoptosis [39, 40] . The extrinsic pathway is activated by the death re- proapoptotic (Bax, Bak, and tBid) members inhibiting and promoting the release, respectively. The release of cytochrome c results in activation of the initiator caspase-9. The activated initiator caspase-8 and caspase-9 then activate the effector caspases cascade, resulting in the classical biochemical and morphological changes associated with the apoptotic phenotype [41, 42] . In our experiments, risperidone increased the expression of Bax, but did not affect the expression of Bcl-2 and caspase-8. These results suggest that risperidone aggravates neuron apoptosis through the intrinsic pathway.
In conclusion, risperidone could enhance the vulnerability to stroke in hypertensive rats via activating the intrinsic apoptotic pathway in neurons as well as endothelium injury. 60, 90 μM) on neurotoxic potential in normal cerebral cortex neurons from SHR-SPs and WKY rats was examined by MTT (n = 6 in each group). The values of MTT and apoptosis rates are expressed as mean ± SD. Dunnett t-test, P > 0.05 for treatment group versus control group.
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